Is Gilead Sciences (GILD) overvalued or fairly valued?

MarketChacha shows Gilead Sciences's valuation in context — a forward P/E of about 13.8, a price-to-book of about 7.0 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is the share price of Gilead Sciences (GILD)?

Gilead Sciences last traded at $133.21 (-0.8% on the day), as of 7/20/2026 — a delayed quote shown for education, not investment advice.

Gilead Sciences

GILD · NASDAQ · Biotech · United States

$133.21-0.8%

Delayed · as reported by Yahoo Finance · as of Jul 20, 2026, 8:00 PM

Snapshot

TickerGILD

ExchangeNASDAQ

SectorBiotech

IndustryDrug Manufacturers - General

CountryUnited States

Employees17,000

HeadquartersFoster City, United States

Market cap$165.4B

P/B7.0

Volume4.09M

Websitewww.gilead.com

Filings tracked0

About Gilead Sciences

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.

Profile as reported by Yahoo Finance.

Who owns it

Insiders0.1%
Institutions93.2%
Public & other6.7%

3,078 institutional holders

As reported by Yahoo Finance.

Top holders

Blackrock Inc.9.59%
Vanguard Capital Management LLC6.50%
FMR, LLC5.79%
State Street Corporation4.82%
Invesco Ltd.3.35%
Capital World Investors3.33%
Vanguard Portfolio Management LLC2.83%
JPMORGAN CHASE & CO2.74%

Largest institutional holders, as reported by Yahoo Finance (as of 3/31/2026).

What's expected next

Next quarter

Rev $7.8B · EPS 2.23

Est. earnings growth -9.8%

Next fiscal year

Rev $32.4B · EPS 9.71

Est. earnings growth +1358.8%

Analyst consensus estimates — not the company's own guidance. As reported by Yahoo Finance.

$107.7552-wk range$157.29

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Ask MarketChacha about GILD

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.